Breye Therapeutics strengthens management team

20 April 2023

Danish clinical-stage retinal diseases biotech Breye Therapeutics today announced the appointment of Peter Adamson as chief scientific Officer (CSO).

Dr Adamson has over 20 years of experience in ophthalmology drug development. He has previously held senior leadership positions at various biopharmaceutical companies including vice president and head of ophthalmology research at UK pharma major GSK (LSE: GSK), where he generated multiple clinical candidates and acted as lead biologist on a number of discovery programs. He previously also worked at ProQR and recently Tenpoint Therapeutics, where he was involved in building pipelines and securing successful financing.

Additionally, Breye has name Gabriela Burian as a new member of its board of directors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK